drugset
drugset / Trial / NCT05011526

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

NCT05011526 ↗

Phase 3 Completed 1030 enrolled Medigen Vaccine Biologics Corp.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to assess the immunogenicity and safety of MVC-COV1901 vaccine compared to AZD1222 in heathy adults.

Timeline

Start
2021-10-08
Primary completion
2021-12-28
Completion
2022-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1222 Vaccine — Intramuscular
Subject MVC-COV1901 Vaccine — Intramuscular

Indications

No indication recorded.